Mabwell(SH:688062) Xin Lang Cai Jing·2025-08-15 01:28Group 1 - The core viewpoint of the news highlights the financial performance and trading activities of Maiwei Biotech, indicating a decline in revenue and net profit, alongside significant trading volumes in the stock market [1][2] - On August 14, 2023, Maiwei Biotech's stock price decreased by 0.64%, with a trading volume of 439 million yuan, and a net financing outflow of 772.01 million yuan [1] - As of August 14, 2023, the total margin balance for Maiwei Biotech was 502 million yuan, with a financing balance of 501 million yuan, representing 6.90% of the circulating market value, indicating a high level of financing activity [1] Group 2 - For the period ending March 31, 2025, Maiwei Biotech reported a revenue of 44.79 million yuan, a year-on-year decrease of 33.70%, and a net profit attributable to shareholders of -292 million yuan, a decline of 41.85% [2] - As of March 31, 2025, the number of shareholders for Maiwei Biotech increased to 16,100, reflecting a 4.22% rise, while the average circulating shares per person decreased by 4.04% to 12,705 shares [2] - The top ten circulating shareholders included several funds, with HSBC Jintrust Smart Manufacturing Pioneer Fund being the third largest, holding 4.705 million shares, a decrease of 136,200 shares from the previous period [2]